Literature DB >> 15511676

The emerging role of interferon in human systemic lupus erythematosus.

Emily C Baechler1, Peter K Gregersen, Timothy W Behrens.   

Abstract

Recent studies of patients with systemic lupus erythematosus, together with data from lupus-prone mice, suggest that inappropriate activation of type I interferon might have a role in disease pathogenesis. Serum levels of IFN-alpha are elevated in SLE patients, and gene expression profiling of peripheral blood cells shows that most lupus cases demonstrate an upregulation of IFN-responsive genes. Of interest, the IFN gene 'signature' correlates with more severe disease. The available data support a model whereby chromatin-containing immune complexes circulating in the blood of lupus patients stimulate leukocytes to produce IFN, which perpetuates disease. These emerging insights into the connection between IFN and lupus provide a host of new diagnostic and therapeutic opportunities.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15511676     DOI: 10.1016/j.coi.2004.09.014

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  77 in total

1.  Myeloid dendritic cells from B6.NZM Sle1/Sle2/Sle3 lupus-prone mice express an IFN signature that precedes disease onset.

Authors:  Uma Sriram; Linda Varghese; Heather L Bennett; Neelakshi R Jog; Debra K Shivers; Yue Ning; Edward M Behrens; Roberto Caricchio; Stefania Gallucci
Journal:  J Immunol       Date:  2012-06-01       Impact factor: 5.422

Review 2.  Interferons in autoimmune and inflammatory diseases: regulation and roles.

Authors:  Divaker Choubey; Kamal D Moudgil
Journal:  J Interferon Cytokine Res       Date:  2011-12       Impact factor: 2.607

Review 3.  Validation of new biomarkers in systemic autoimmune diseases.

Authors:  Maria G Tektonidou; Michael M Ward
Journal:  Nat Rev Rheumatol       Date:  2011-11-01       Impact factor: 20.543

4.  Systemic sclerosis and lupus: points in an interferon-mediated continuum.

Authors:  Shervin Assassi; Maureen D Mayes; Frank C Arnett; Pravitt Gourh; Sandeep K Agarwal; Terry A McNearney; Damien Chaussabel; Nancy Oommen; Michael Fischbach; Kairav R Shah; Julio Charles; Virginia Pascual; John D Reveille; Filemon K Tan
Journal:  Arthritis Rheum       Date:  2010-02

5.  Inhibition of a C-rich oligodeoxynucleotide on activation of immune cells in vitro and enhancement of antibody response in mice.

Authors:  Guang Yang; Min Wan; Yongsheng Zhang; Luguo Sun; Ran Sun; Dali Hu; Xiaojing Zhou; Li Wang; Xiuli Wu; Liying Wang; Yongli Yu
Journal:  Immunology       Date:  2010-12       Impact factor: 7.397

6.  Bisphenol A (BPA) stimulates the interferon signaling and activates the inflammasome activity in myeloid cells.

Authors:  Ravichandran Panchanathan; Hongzhu Liu; Yuet-Kin Leung; Shuk-mei Ho; Divaker Choubey
Journal:  Mol Cell Endocrinol       Date:  2015-08-12       Impact factor: 4.102

Review 7.  New therapies and preventive strategies to treat and minimize damage in lupus.

Authors:  Henda Bouali; Gary Gilkeson
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.592

Review 8.  Dendritic cells: potential triggers of autoimmunity and targets for therapy.

Authors:  J A Hardin
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

9.  Essential requirement for IRF8 and SLC15A4 implicates plasmacytoid dendritic cells in the pathogenesis of lupus.

Authors:  Roberto Baccala; Rosana Gonzalez-Quintial; Amanda L Blasius; Ivo Rimann; Keiko Ozato; Dwight H Kono; Bruce Beutler; Argyrios N Theofilopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

10.  IFN regulatory factor 5 is required for disease development in the FcgammaRIIB-/-Yaa and FcgammaRIIB-/- mouse models of systemic lupus erythematosus.

Authors:  Christophe Richez; Kei Yasuda; Ramon G Bonegio; Amanda A Watkins; Tamar Aprahamian; Patricia Busto; Rocco J Richards; Chih Long Liu; Regina Cheung; Paul J Utz; Ann Marshak-Rothstein; Ian R Rifkin
Journal:  J Immunol       Date:  2009-12-09       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.